Sydney, Australia 6 June 2022 Highlights IND approval received for SAR-Bombesin product, enabling a Phase II “SABRE” imaging trial to detect prostate cancer in up to 50 PSMA-negative participants in the US Approximately 20% of prostate cancer patients with biochemical recurrence are PSMA-PET negative and therefore unsuitable for the currently approved PSMA targeting agents, presenting…
Sydney, Australia 31 May 2022 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce the acquisition of a targeted nanobody platform to its Discovery pipeline. The intellectual property, including a provisional patent and know-how, has been acquired from leading nanotechnology researcher…
Sydney, Australia 26 May 2022 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce that Dr Neal Shore has joined Clarity’s Clinical Advisory Board (CAB). Dr Shore MD, FACS is the Chief Medical Officer of Urology/Surgical Oncology at GenesisCare, US and…
Sydney, Australia 5 May 2022 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, confirms Clarity and its clinical development programs are unaffected by Novartis’ recent suspension of production of Lutathera® and Pluvicto™/ 177Lu-PSMA-617 at its facilities in Ivrea, Italy and Millburn, New Jersey. On…
Sydney, Australia 21 April 2022 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce that it has successfully treated its first participant in the diagnostic US-based 64Cu SAR-bisPSMA trial for patients with biochemical recurrence (BCR) of prostate cancer. COBRA (Copper-64 SAR-bisPSMA in Biochemically Recurrent…
Sydney, Australia 5 April 2022 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce that Dr Andrei Iagaru has joined Clarity’s Scientific Advisory Board (SAB). Dr Iagaru is a Professor of Radiology – Nuclear Medicine and the Chief of the Division of…
Sydney, Australia 4 April 2022 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce the appointment of David Green as Chief Financial Officer (CFO). Outgoing CFO Robert Vickery will continue to serve as Company Secretary. Mr Green joins Clarity with over…
Sydney, Australia 28 March 2022 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce that the diagnostic 64Cu SAR-bisPSMA trial (COBRA NCT052491271) for patients with prostate cancer is open for recruitment. COBRA (COpper-64 SAR-BisPSMA in Biochemically Recurrent prostAte cancer) is a Phase I/II Positron Emission…
Sydney, Australia 24 March 2022 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce that an investigator-initiated trial (IIT) will commence shortly in the US investigating 64Cu SAR-bisPSMA in prostate cancer (NCT05286840)1. The X-Cancer’s investigator-led trial of SAR-bisPSMA…
Sydney, Australia 28 February 2022 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to provide an update regarding the Company’s negotiations with China Grand Pharmaceutical and Healthcare Holdings Limited (China Grand). As noted in the Company’s Prospectus, Clarity and China Grand agreed…